GHRP-2
Also known as: Growth Hormone Releasing Peptide-2, Pralmorelin
A synthetic GH secretagogue studied in human hormone-response, diagnostic and food-intake experiments. These findings do not establish a routine muscle-building protocol, appetite-sparing dieting aid or long-term combination benefit.
Quick Facts
What Is GHRP-2?
GHRP-2 is a synthetic GH secretagogue. A diagnostic study evaluated GH responses in 77 healthy participants and 58 patients with severe GH deficiency defined by insulin-tolerance testing. A diagnostic response does not establish an effective muscle-building or general anti-aging treatment.
Mechanism and Non-GH Hormones
In a ten-man IV study, GHRP-2 increased GH, ACTH and prolactin responses, with greater responses during fasting; vasopressin was not stimulated. This is not GH-only selectivity or proof that meal timing improves clinical outcomes. The GHRP-2/hexarelin comparison also reports non-GH hormonal responses; its indexed abstract contains incomplete sentences, so detailed numerical comparisons are not relied on here.
What Has Been Demonstrated?
| Research context | Existing findings, population and limits |
|---|---|
| Diagnostic response study | The diagnostic study found a reproducible GH response that distinguished severe GH deficiency under its assay and testing conditions. That result should not be treated as a self-diagnosis cutoff or evidence of routine fat loss, appetite control, better sleep or recovery. A larger acute GH response is not a clinical benefit ranking. |
| Subcutaneous food-intake experiment | A small crossover food-intake experiment used subcutaneous GHRP-2 infusion in seven lean healthy men. They ate more at the test meal than with saline. This is direct human evidence against presenting GHRP-2 as free of appetite stimulation or inherently useful for dieting; it is not a chronic weight-outcome trial. |
Research Dosing and Route
The diagnostic study used a 100-microgram intravenous dose after overnight fasting. This was a supervised provocative test, not a validated repeated subcutaneous regimen, bodybuilding dose or home diagnostic procedure. Its findings do not supply a general timing, titration or cycling plan.
Comparative and Diagnostic Research
Human research shows that fasting can alter measured GH and other pituitary responses. Such differences matter when interpreting an experiment, but they do not establish that GHRP-2 is better than GHRP-6 for dieting or that combining secretagogues improves long-term outcomes.
FDA Safety Findings and Causal Limits
The FDA safety record identifies immunogenicity and peptide-characterization concerns for injectable and nasal GHRP-2. It also notes reports of increased insulin requirements, deaths among critically ill subjects, infection and pancreatitis; causality has not been established. These reports warrant attention without being presented as proven GHRP-2-caused events or as a risk rate for a different population and product.
Combination and Long-Term Questions
The acute GHRH/GHRP-6 study supports a reason to study complementary pathways. It did not test sermorelin/ipamorelin, CJC-1295/ipamorelin or a general multi-peptide recovery stack. A larger GH signal does not establish better muscle gain, fat loss, sleep or long-term safety. The cited evidence does not establish a protective cycling or receptor-reset calendar.
Sources and Review Scope
Editorial source check: October 26, 2026. Publication findings were checked through indexed abstracts; journal full texts were not reviewed. The cited official product or regulatory records were read for the claims described. This is an editorial source revision, not clinician signoff or clearance of every related guide, tool, comparison or product.
Frequently Asked Questions About GHRP-2
Both have human GH-response findings. The cited studies do not establish a general clinical benefit or safety ranking for muscle gain, recovery or dieting.
A small human subcutaneous-infusion experiment increased food intake. GHRP-2 should not be described as appetite-sparing on the basis of its GH response; the cited studies do not establish a weight-loss regimen.
The studies do not establish a universal visible-results timeline. A hormone response is not proof of a clinical benefit.
A larger acute GH result does not prove better clinical outcomes. No general winner is established by these sources.
The reviewed evidence does not establish a validated combination schedule or long-term stack benefit.
The FDA record concerns compound- and route-specific compounding risks. Approval and legal eligibility of an actual preparation are separate questions; a prescription or availability alone does not settle them.
Related Peptides
Continue exploring GHRP-2
- GHRP-2 (Pralmorelin): Dosing, Uses and What the Evidence ShowsGuide
- GHRP-2 vs GHRP-6: GH, Appetite & Human Evidence [2026]Comparison
- Ipamorelin vs GHRP-2: Growth Hormone Releasing Peptides ComparedComparison
Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.